Status Epilepticus: Convulsive & Non-Convulsive

Status Epilepticus: Convulsive & Non-Convulsive

Status epilepticus ($SE$) is among the most common and devastating neurological emergencies encountered in the neuro-intensive care unit, with an annual incidence of 10 to 40 per 100,000 and an in-hospital mortality reaching $15\text{--}20\%$. Successful management hinges on rapid, protocol-driven treatment that parallels the molecular progression of the condition from self-terminating network hypersynchrony to irreversible, pharmacoresistant excitotoxic injury.

---

Operational Definitions: The 2015 ILAE Classification ($t_1$ and $t_2$)

Historically, status epilepticus was defined as continuous seizure activity lasting $\ge 30\text{ minutes}$, or recurrent seizures without full interictal return to baseline neurological status. However, basic neurobiology and clinical trials revealed that waiting 30 minutes before initiating aggressive therapy results in severe pharmacoresistance and profound neuronal loss. In 2015, the International League Against Epilepsy ($ILAE$) established a conceptual and operational framework incorporating two distinct, semiology-specific timepoints:

1. Timepoint 1 ($t_1$): The time when a seizure has abnormally exceeded its physiological duration, indicating that endogenous mechanisms of seizure termination have failed. Treatment must be initiated immediately at $t_1$.
2. Timepoint 2 ($t_2$): The time of ongoing epileptic activity beyond which there is a substantial risk of long-term neuronal necrosis, network alteration, and functional deficit. Pharmacoresistance accelerates dramatically after $t_2$.

---

Stabilization and Initial Benzodiazepine Therapy

The initial phase of status epilepticus requires immediate administration of a fast-acting, high-potency benzodiazepine to enhance synaptic $GABA_A$ receptor-mediated chloride conductances and terminate synchronous cortical depolarization.

• IV lorazepam: 0.1 mg/kg, maximum 4 mg per dose, administered at an appropriate rate and repeatable once if seizures persist. Prepare airway and respiratory support; adequate treatment should not be withheld solely from fear of respiratory depression during ongoing convulsive status.

The Landmark RAMPART Trial (NEJM 2012)

The Rapid Anticonvulsant Medication Prior to Arrival Trial ($RAMPART$) evaluated 893 prehospital status epilepticus patients randomized to receive either intramuscular midazolam via autoinjector ($10\text{ mg}$) or intravenous lorazepam ($4\text{ mg}$). The trial established two paradigm-shifting findings:

• Non-Inferiority & Superior Rapid Cessation: Intramuscular midazolam was statistically non-inferior and clinically superior in achieving rapid seizure cessation upon arrival in the emergency department ($73.4\%$ vs. $63.4\%$, $p < 0.001$).
• The Paradox of Vascular Access: Although IV lorazepam has a faster onset once injected, establishing IV access in an actively convulsing patient requires an average of 4 to 8 minutes. Intramuscular administration eliminated this access delay, resulting in significantly faster overall time from paramedic arrival to medication delivery and seizure termination.

---

Prompt Second-Line Therapy for Benzodiazepine-Refractory Status

Seizures persisting despite full, weight-appropriate first-line benzodiazepine administration enter Phase 2, termed Established Status Epilepticus ($ESE$). Phase 2 demands immediate initiation of a non-sedating intravenous antiseizure medication ($ASM$) to prevent recurrence and suppress emerging pharmacoresistance.

The Landmark ESETT Trial (NEJM 2019)

For decades, fosphenytoin was empirically presumed superior for benzodiazepine-refractory SE. The landmark Established Status Epilepticus Treatment Trial ($ESETT$) prospectively tested this assumption in a multicenter, randomized, double-blind, comparative-effectiveness trial of 384 children and adults with benzodiazepine-refractory convulsive SE lasting $\ge 5\text{ minutes}$:

• Treatment Arms:
  • Levetiracetam: $60\text{ mg/kg}$ IV (maximum $4500\text{ mg}$) infused over 10 minutes.
  • Fosphenytoin: $20\text{ mg PE/kg}$ IV (maximum $1500\text{ mg PE}$) infused at $150\text{ mg PE/min}$.
  • Sodium Valproate: $40\text{ mg/kg}$ IV (maximum $3000\text{ mg}$) infused over 10 minutes.
• Primary Finding: The primary endpoint (cessation of status epilepticus and improvement in responsiveness at 60 minutes without rescue therapy) occurred in $47\%$ of the levetiracetam group, $45\%$ of the fosphenytoin group, and $46\%$ of the valproate group. There were no statistically significant differences in efficacy among the three agents.
• Safety Profile: No significant safety difference was demonstrated among the treatment groups; this does not prove identical risks in every patient.

---

Non-Convulsive Status Epilepticus (NCSE)

Non-convulsive status epilepticus ($NCSE$) is defined as a persistent state of electrographic seizure activity lasting $\ge 10\text{ minutes}$ resulting in altered mental status or sensory/behavioral deficits without prominent bilateral convulsive motor movements. In the neuro-ICU, NCSE is diagnosed in $10\text{--}40\%$ of patients with unexplained altered mental status following cardiac arrest, acute ischemic stroke, intracerebral hemorrhage, traumatic brain injury, or sepsis.

Clinical Presentation

NCSE presents subtly across a spectrum of encephalopathic findings:

• Unexplained coma or failure to awaken after convulsive status epilepticus or neurotrauma
• Fluctuating delirium, confusion, catatonia, or episodic mutism
• Subtle motor "micro-signs": micro-clonus of the eyelids, subtle facial twitching, rhythmic nystagmus or ocular deviation, and continuous perioral automatisms

EEG Diagnosis Requires Duration and Context

Under ACNS 2021 terminology, an electrographic seizure includes epileptiform discharges averaging more than 2.5 Hz for at least ten seconds or a pattern with definite evolution lasting at least ten seconds. Electrographic status is at least ten continuous minutes of seizure or seizures occupying at least 20% of any sixty-minute period. One ten-second seizure is not automatically status epilepticus. Clinical correlates and electroclinical responses to medication can add important evidence. Ictal-interictal continuum patterns do not all require anesthetic coma.

The AES convulsive algorithm describes stabilization during 0–5 minutes, initial benzodiazepine treatment during 5–20 minutes, second therapy during 20–40 minutes, and further escalation after that. These are phase markers, not instructions to delay medication. Treat a continuing five-minute convulsion promptly, prepare the next agent while administering the benzodiazepine, and escalate when adequate initial therapy fails. Confirm that the drug was actually delivered and that glucose and other immediately reversible causes are addressed.

Source: AES guideline and ACNS 2021 terminology.